Anti-cd37 immunoconjugate and anti-cd20 antibody combinations
AssigneeImmunoGen, Inc.
InventorsAngela ROMANELLI, Rodrigo R. RUIZ-SOTO, Jose PONTE, Jutta DECKERT, Jan PINKAS
Life of this patent
Estimating the term…
Abstract
Methods of administering immunoconjugates that bind to CD37 (e.g., IMGN529) in combination with antibodies that bind to CD20 are provided. The methods comprise administering an anti-CD37 immunoconjugate (e.g., IMGN529) and an anti-CD20 antibody to a person in need thereof, for example, a cancer patient.
Claims52
A method for treating a patient having a B-cell cancer comprising administering to said patient in need thereof an immunoconjugate that binds to CD37 comprising an antibody or antigen-binding fragment thereof comprising VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences as set forth in SEQ ID NOs:
- 4-9, respectively;
- and an antibody or antigen-binding fragment thereof that binds to CD20, wherein said immunoconjugate that binds to CD37 is administered at a dose of about 0.7 mg/kg.
(canceled)
11-16. (canceled)
A method for treating a patient having a B-cell cancer comprising administering to said patient in need thereof an immunoconjugate that binds to CD37 comprising an antibody or antigen-binding fragment thereof comprising VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences as set forth in SEQ ID NOs:
- 4-9, respectively;
- and an antibody or antigen-binding fragment thereof that binds to CD20, and wherein the antibody or antigen-binding fragment thereof that binds to CD20 is not rituximab.
18-19. (canceled)
21-25. (canceled)
27-30. (canceled)
(canceled)
37-42. (canceled)
44-47. (canceled)
49-65. (canceled)
(canceled)
(canceled)
71-72. (canceled)
75-76. (canceled)
(canceled)
80-83. (canceled)
(canceled)
88-92. (canceled)
A kit comprising a pharmaceutical composition comprising an immunoconjugate that binds to CD37 comprising an antibody comprising VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences as set forth in SEQ ID NOs:
- 4-9, respectively;
- and instructions to administer the immunoconjugate and an anti-CD20 antibody or antigen-binding fragment thereof.
96-102. (canceled)
A method of instructing a human subject with cancer, the method comprising providing instructions to receive cancer treatment with an immunoconjugate that binds to CD37 and an antibody or antigen-binding fragment thereof that binds to CD20.
104-109. (canceled)
Dependencies are inferred from the claim text.